Lv7
4370 积分 2024-06-26 加入
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
4天前
已完结
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
4天前
已完结
MA01.05 Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC
15天前
已完结
The Society of Thoracic Surgeons Expert Consensus Pathway for Robotic Cardiac Surgical Training
23天前
已完结
The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial
1个月前
已完结
Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer
1个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
2个月前
已完结
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
2个月前
已关闭
Small Cell Lung Cancer
3个月前
已完结
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
3个月前
已完结
皖公网安备34019202002308
